Plasma concentration of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) were measured by radioimmunoassay in 45 patients with benign and malignant ovarian diseases. All patients with ovarian carcinoma showed increased beta-TG and PF4 levels. Among benign ovarian diseases the patients with serous cystadenoma more frequently showed signs of platelet activation, whereas those with endometriotic cyst and mucinous cystadenoma generally had normal beta-TG and PF4 values. These results indicate that an increased platelet activation is consistently associated with malignant tumors of the ovary, whereas benign tumors show a different capacity to induce platelet activation.
GasicG.I., GasicT.B., GalantiN., JohnsonT., MurphyS.: Platelet tumor cell interaction in mice.The role of platelets in the spread of malignant disease. Int. J. Cancer, 11: 704–718, 1973.
KaplanK.L., NosselH.L., DrillingM.: Radioimmunoassay of platelet factor 4 and beta-thromboglobulin: development and application to studies of platelet release in relation to fibrino-peptide A generation.Br. J. Haematol., 39: 129, 1978.
5.
KaplanK.L., OwenJ.: Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo.Blood, 57: 199–202, 1981.
6.
KarpatkinS., PearlsteinE.: Role of platelets in tumor cell metastases (Review Article).Ann. Intern. Med., 95: 636–641, 1981.
7.
LaghiF., Di RobertoP.F., Benedetti PaniciP., MargaritiP.A., ScribanoD., CudilloL., VillaniL., BizziB.: Coagulation disorders in patients with tumors of the uterus.Tumori, 69: 349–353, 1983.
8.
LernerW.A., PearlsteinE., AmbrogioC., KarpatkinS.: A new mechanism for tumor-induced platelet aggregation.Comparison with mechanisms shared by other tumors with possible pharmacologic strategy toward prevention of metastases. Int. J. Cancer, 31: 463–469, 1983.
9.
LudlamC.A.: Evidence for the platelet specifity of beta-thromboglobulin studies on its plasma concentration in healthy individuals.Br. J. Haematol., 41: 271, 1979.
10.
MooreS., PepperD.S., CashJ.D.: The isolation and characterization of a platelet-specific beta-globulin (beta-thromboglobulin) and detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets.Biochem. Biophys. Acta, 379: 360–369, 1975.
11.
NicolsonG.L.: Cell surface and blood-borne tumor metastasis.Prog. Cancer Res. Ther., 5: 163–164, 1977.
12.
OgstonD., BennetB.: Naturally occurring inhibitors of coagulation. In: Haemostasis: Biochemistry, Physiology and Pathology, OgstonD., and BennetB. (Eds.), p. 230, John Wiley and Sons, London, 1977.
13.
PearlsteinE., CooperL.B., KarpatkinS.: Extraction and characterization of a platelet-aggregating material (PAM) from SV-40 transformed mouse 3T3 fibroblasts.J. Lab. Clin. Med., 93: 332–334, 1979.
14.
SchickP.: The role of platelet membrane lipids in platelet hemostatic activities.Semin. Hematol., 16: 221, 1979.
15.
WarrenB.A.: Environment of the blood-borne tumor embolus adherent to vessel wall.J. Med., 4: 150–177, 1973.
16.
ZahaviT., KakkarV.V.: Beta-thromboglobulin, a specific marker of in vivo platelet release reaction.Thromb. Haemost., 44: 23–29, 1980.
